Pharma 4.0 Market Size To Reach $35.79 Billion By 2030

Pharma 4.0 Market Growth & Trends

The global pharma 4.0 market size is expected to reach USD 35.79 billion by 2030, registering a CAGR of 18.96% from 2024 to 2030, according to a new report by Grand View Research, Inc. The pharma 4.0 market is being driven by several key factors, including the rising demand for personalized medicine, the need for improved efficiency and cost reduction, supply chain optimization, and an increasing focus on patient-centric approaches. The growing prevalence of chronic disorders and rare diseases has heightened the demand for personalized medicine. Pharma 4.0 technologies, such as additive manufacturing (3D printing) and modular production facilities, enable the production of personalized medicines and small batches tailored to individual patient needs, supporting this trend.

In addition, increasing adoption of digital technologies is driving the market growth. These technologies optimize, improve, and revolutionize drug development, manufacturing, distribution, and patient care. Blockchain technology has significantly reshaped supply chain management by offering transparency, traceability, and optimization, reducing stockouts, preventing counterfeiting, and enhancing overall efficiency and patient safety.

Furthermore, the market growth is being driven by increasing investments from pharmaceutical companies in adopting Pharma 4.0 technologies. For example, AstraZeneca signed a deal worth up to USD 840 million for the target identification of rare neurodegenerative and neuromuscular diseases. As part of this deal, AstraZeneca’s Alexion division will collaborate with Verge Genomics to identify drug targets for these conditions. Over the course of the four-year, multi-target agreement, the companies will utilize machine learning to analyze Verge’s genomic datasets, which are derived from human tissue rather than cell or animal models.

 Request a free sample copy or view report summary: Pharma 4. 0 Market Report

Pharma 4. 0 Market Report Highlights

• On the basis of type, the software segment dominated the market in 2023, owing to the increasing adoption of software due to various benefits such as efficiency enhancement, improved compliance and productivity. In addition, the IoT enabled software help in real time monitoring and tracking of manufacturing process, leading to better process control and reduces the downtime

• On the basis of technology, the AI & ML segment held the largest market share owing to growing adoption of AI and increasing investments. For instance, as per a survey, over 75% of pharma executives plan to apply AI to speed drug discovery by 2025

• On the basis of application, the drug discovery & development dominated the market in 2023 due to increased investment in AI for drug discovery startups

• Pharma & biotech segment held the largest market share of 49.8% in 2023. Pharmaceutical companies are increasingly adopting Pharma 4.0 technologies to enhance efficiency, productivity, and quality in their manufacturing processes thereby driving the segment growth

• North America dominated the global market with a revenue share of 41.12% in 2023. The growth is attributed to the increasing government initiative, technological advancement in the healthcare industry, and a strong presence of key market players

Pharma 4.0 Market Segmentation

Grand View Research has segmented the global pharma 4.0 market based on type, technology, application, end-use and region:

Pharma 4.0 Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Software

• Services

Pharma 4.0 Technology Outlook (Revenue, USD Billion, 2018 - 2030)

• AI & ML

• Big Data Analytics

• IoT

• Blockchain Technology

• Others (Digital twin, Advanced robotics, AR &VR)

Pharma 4.0 Application Outlook (Revenue, USD Billion, 2018 - 2030)

• Drug Discovery & Development

• Manufacturing

• Supply Chain Management

• Others (Product Lifecycle Management, Personalized Medicine, Regulatory Compliance)

Pharma 4.0 End Use Outlook (Revenue, USD Billion, 2018 - 2030)

• Pharma & Biotech companies

• Healthcare Providers

• CRO & CDMO

Pharma 4.0 Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Spain

  • Italy

  • Norway

  • Denmark

  • Sweden

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • UAE

  • Saudi Arabia

  • South Africa

  • Kuwait

List of Key Players in the Pharma 4.0 Market

• Microsoft Corporation

• IBM

• Amazon Web Service (AWS)

• SAP

• Oracle

• GE Healthcare

• Siemens Healthineers

• Cisco

• Cinntra

• Dassault Systems

• Nexocode